Terlipressin vs placebo or no intervention: Serious adverse events: cardiovascular events
Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Terlipressin vs placebo or no intervention Serious cardiovascular adverse events · people with hepatorenal syndrome Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty). Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome (2017) · Cochrane Headline outcomes only | RR 7.26 [1.7, 31.05] | 4 studies · 234 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.